Answers are grounded in this paper and cite their sources.
Preclinical study reveals that GPR89 regulates endoplasmic reticulum pH in breast cancer cells, highlighting a tumor-specific therapeutic target.
How cancers regulate endoplasmic reticulum (ER) pH and minimize ER stress remains unclear. Here we show that in breast cancer, these processes are governed by the anion channel GPR89. While normally localized to the Golgi, we find GPR89 is also present in the ER of tumor cells, where it collaborates with vacuolar H⁺ ATPase to regulate pH, and reduces ER stress via IRE1α-HSP47-XBP1s, ATF6 and ATP2A2 pathways. This ER localization of GPR89 drives a tumor-specific dependency, rendering breast cancer cells, but not normal tissues, dependent on this anion channel. Structural modeling and mutagenesis identify five key amino acids essential for GPR89’s ER pH regulatory function and tumor cell survival. Consistent with its cancer-specific functions, GPR89 cooperates with Myc to accelerate mammary tumorigenesis. These findings uncover how breast cancers adapt to oncogenic stress by co-opting Golgi mechanisms of pH regulation to support ER homeostasis and survival. Oncogene-driven endoplasmic reticulum (ER) stress is common in cancer. Here, authors show breast cancers extend Golgi anion channel GPR89 to the ER to mitigate this stress, creating a potentially targetable dependency and new therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Ferro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: